The Bunick lab discovered an assembly mechanism critical for intermediate filament proteins to form mature filaments. We have developed a therapeutic that harnesses this unique mechanism to disrupt vimentin filament formation. Vimentin is required for the progression and metastasis of lung cancer. Our targeted therapeutic disrupts vimentin assembly to provide an innovative solution to the clinical burden of lung cancer, with the patient benefit being reduced cancer burden and limited systemic spread.